About Insmed
Insmed is a company based in Bridgewater (United States) founded in 1999.. The company has 1,270 employees as of December 31, 2024. Insmed has completed 2 acquisitions, including Adrestia and Transave. Insmed offers products and services including ARIKAYCE, Brensocatib, and TPIP. Insmed operates in a competitive market with competitors including Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others.
- Headquarter Bridgewater, United States
- Employees 1270 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Insmed Incorporated
-
Annual Revenue
$363.71 M19.17as on Dec 31, 2024
-
Net Profit
$-913.77 M-21.91as on Dec 31, 2024
-
EBITDA
$-775.56 M-15.69as on Dec 31, 2024
-
Latest Funding Round
$450 M (USD), Post-IPO
Jan 01, 2018
- Investors
-
Employee Count
1270
as on Dec 31, 2024
-
Investments & Acquisitions
Adrestia
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Insmed
Insmed is a publicly listed company on the NASDAQ with ticker symbol INSM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Insmed
Insmed offers a comprehensive portfolio of products and services, including ARIKAYCE, Brensocatib, and TPIP. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for nontuberculous mycobacterial lung disease via inhalation.
Inhibitor targeting inflammatory diseases in clinical development.
Early-stage compound for potential disease therapies.
Unlock access to complete
Leadership Team
172 people
Software Development Team
54 people
Operations Team
36 people
Senior Team
34 people
Sales and Marketing
30 people
Product Management Team
21 people
Legal and Compliance
17 people
Finance and Accounting
15 people
Unlock access to complete
Funding Insights of Insmed
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $450.0M
-
First Round
First Round
(17 Dec 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2018 | Amount | Post-IPO - Insmed | Valuation |
investors |
|
| Dec, 2010 | Amount | Grant - Insmed | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Insmed
Insmed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include United States Department of Agriculture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Leadership is provided on agriculture, food, and rural development matters.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Insmed
Insmed has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adrestia and Transave. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical drugs for multiple therapeutic areas are manufactured.
|
2018 | ||||
|
Developer of inhaled pharmaceuticals for the site-specific treatment of serious lung infections
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Insmed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Insmed Comparisons
Competitors of Insmed
Insmed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Provider of human monoclonal antibodies against infectious diseases
|
|
| domain | founded_year | HQ Location |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
|
| domain | founded_year | HQ Location |
Microbiome therapies are developed for treating intestinal dysbiosis diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Insmed
Frequently Asked Questions about Insmed
When was Insmed founded?
Insmed was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Where is Insmed located?
Insmed is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Who is the current CEO of Insmed?
Will Lewis is the current CEO of Insmed.
How many employees does Insmed have?
As of Dec 31, 2024, the latest employee count at Insmed is 1,270.
What is the annual revenue of Insmed?
Annual revenue of Insmed is $363.71M as on Dec 31, 2024.
What does Insmed do?
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Who are the top competitors of Insmed?
Insmed's top competitors include Aridis Pharma, MaaT Pharma and Basilea.
What products or services does Insmed offer?
Insmed offers ARIKAYCE, Brensocatib, and TPIP.
Is Insmed publicly traded?
Yes, Insmed is publicly traded on NASDAQ under the ticker symbol INSM.
How many acquisitions has Insmed made?
Who are Insmed's investors?
Insmed has 1 investor. Key investors include United States Department of Agriculture.
What is Insmed's ticker symbol?
The ticker symbol of Insmed is INSM on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.